Completed

Automated Physician Directed Messaging Impact on Patient Engagement in Digital Diabetes Prevention Program

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to investigate how automated messages from physicians can improve your engagement in a digital diabetes prevention program.

What is being tested

Digital diabetes prevention program (dDPP)

+ Adapted dDPP-EHR tool

Other
Who is being recruted

Hyperglycemia+2

+ Metabolic Diseases

+ Nutritional and Metabolic Diseases

From 18 to 99 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Services Research Study

Interventional
Study Start: February 2021
See protocol details

Summary

Principal SponsorNYU Langone Health
Last updated: January 31, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2021

Actual date on which the first participant was enrolled.

This study focuses on individuals with pre-diabetes who are using a digital Diabetes Prevention Program (dDPP) application. The main goal is to understand how automated messages from physicians can impact patient engagement in this digital program. The importance of this research lies in its potential to improve care for those at risk of developing diabetes, by enhancing their participation in preventive measures. Half of the 400 participants will receive automated, targeted messages as part of the intervention group. The study will track changes in Body Mass Index (BMI) and body weight, which are calculated using height from electronic health records and weight from remote Bluetooth-connected weight scales. Additionally, it will measure changes in Hemoglobin A1c (HbA1c) levels, a key indicator of blood sugar control, using home test kits and electronic health records. These measurements will be taken at enrollment, and then at 3, 6, 9, and 12 months. The results will be compared to baseline to assess the effectiveness of the automated messaging intervention.

Official TitleA Randomized Control Trial to Study the Effects of Automated Physician Directed Messaging on Patient Engagement in a Digital Diabetes Prevention Program
NCT04773834
Principal SponsorNYU Langone Health
Last updated: January 31, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

551 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Services Research Study

These studies look at how healthcare is delivered, managed, and organized. They aim to improve care quality, patient experience, and access to treatment.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 99 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

HyperglycemiaMetabolic DiseasesNutritional and Metabolic DiseasesGlucose IntoleranceGlucose Metabolism Disorders

Criteria

6 inclusion criteria required to participate
18 years or older, BMI ≥ 25 kg/m2 (> 22 kg/m2 if self-identified as Asian)
Must be a NYU Langone patient
A diagnosis of prediabetes (either diagnosis of prediabetes or an HbA1C level of 5.7%-6.4% in past 12 months) or diabetes risk factors (BMI ≥ 25 kg/m2 or > 22 kg/m2 if self-identified as Asian
Safe to engage in moderate physical exercise (as determined by their PCP)
Show More Criteria
4 exclusion criteria prevent from participating
Diagnosed with diabetes
Patients whose weight may vary considerably over the study's timeframe for reasons other than the intervention (e.g. cancer, pregnancy, ascites, severe CHF)
Patients with severe psychiatric disease or dementia
Active health condition that prevents them from engaging in moderate exercise

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Participants will be enrolled virtually into the digital diabetes prevention program through the Noom app and willing to receive general text messages from the study team

Group II

Experimental
Participants will be enrolled virtually into a digital diabetes prevention program through the Noom app and willing to receive text messages based on their engagement levels in Noom from the study team, as well as complete text-based surveys.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

NYU Langone Health

New York, United StatesOpen NYU Langone Health in Google Maps
CompletedOne Study Center